Key partnerships unlock protein access across APAC and the Middle East

Biotech firm Nuclera is accelerating its commercial momentum with a major move into Asia-Pacific and Middle Eastern markets through a network of new distribution agreements. The Cambridge-based company, known for its eProtein Discovery™ System that simplifies and speeds up protein expression, has signed partnerships across China, Japan, South Korea, Singapore, Taiwan, and Israel.

The expansion reflects Nuclera’s shift from early-stage innovation to global commercial execution. Its new regional partners - including MineBio Life Sciences (China), Kiko Tech (Japan), Chayon Laboratories (South Korea), Sciencewerke (Singapore), Cold Spring Biotech (Taiwan), and Yair Or Technologies (Israel) - will provide localised sales and technical support to a growing customer base in pharma, biotech, and academia.

With protein targets underpinning most modern drug discovery efforts, demand is rising for tools that take the complexity out of producing high-quality, functional proteins. Nuclera’s platform enables researchers to move quickly from gene to protein using a compact, automated benchtop system that supports both cell-free and cell-based workflows - now including membrane proteins.

“This is a major step forward in making protein expression faster and more accessible for scientists globally,” said Dr Michael Chen, Nuclera CEO and co-founder. “Our presence in these new markets allows us to better serve customers where they are, through trusted local partners.”

The move follows Nuclera’s recent Series C fundraising and the first CRO installation of its system - milestones that signal strong commercial traction.

Chief Commercial Officer Joseph Bertelsen added: “Building these partnerships is about more than footprint - it’s about enabling hands-on support and scaling our customer relationships in high-potential markets. We’re excited to see where this next phase of growth takes us.”

More information online